Lais Machado de Oliveira1,2, Egberto Reis Barbosa2, Camila Catherine Aquino3, Renato Puppi Munhoz1,4, Alfonso Fasano1,4, Rubens Gisbert Cury2. 1. The Edmond J. Safra Program in Parkinson's Disease and Morton and Gloria Shulman Movement Disorders Clinic, University Health Network, Toronto Western Hospital, Division of Neurology University of Toronto Toronto Ontario Canada. 2. Movement Disorders Center, Department of Neurology, School of Medicine University of São Paulo São Paulo Brazil. 3. Department Health Research Methods, Evidence, and Impact McMaster University Hamilton Ontario Canada. 4. Krembil Brain Institute Toronto Ontario Canada.
Abstract
BACKGROUND: Deep brain stimulation (DBS) is an effective treatment for Parkinson's disease (PD), and careful selection of candidates is a key component of successful therapy. Although it is recognized that factors such as age, disease duration, and levodopa responsiveness can influence outcomes, it is unclear whether genetic background should also serve as a parameter. OBJECTIVES: The aim of this systematic review is to explore studies that have evaluated DBS in patients with mutations in PD-related genes. METHODS: We performed a selective literature search for articles regarding the effects of DBS in autosomal dominant or recessive forms of PD or in PD patients with genetic risk factors. Data regarding changes in motor and nonmotor scores and the presence of adverse events after the stimulation were collected. RESULTS: A total of 25 studies were included in the systematic review, comprising 135 patients. In the shorter term, most patients showed marked or satisfactory response to subthalamic DBS, although leucine rich repeat kinase 2 carriers of R114G mutations had higher rates of unsatisfactory outcome. Longer term follow-up data were scarce but suggested that motor benefit is sustained. Patients with the glucosidase beta acid (GBA) mutation showed higher rates of cognitive decline after surgery. Motor outcome was scarce for pallidal DBS. Few adverse events were reported. CONCLUSIONS: Subthalamic DBS results in positive outcomes in the short term in patients with Parkin, GBA, and leucine-rich repeat kinase 2 (non-R144G) mutations, although the small sample size limits the interpretation of our findings. Longer and larger cohorts of follow-up, with broader nonmotor symptom evaluations will be necessary to better customize DBS therapy in this population.
BACKGROUND: Deep brain stimulation (DBS) is an effective treatment for Parkinson's disease (PD), and careful selection of candidates is a key component of successful therapy. Although it is recognized that factors such as age, disease duration, and levodopa responsiveness can influence outcomes, it is unclear whether genetic background should also serve as a parameter. OBJECTIVES: The aim of this systematic review is to explore studies that have evaluated DBS in patients with mutations in PD-related genes. METHODS: We performed a selective literature search for articles regarding the effects of DBS in autosomal dominant or recessive forms of PD or in PD patients with genetic risk factors. Data regarding changes in motor and nonmotor scores and the presence of adverse events after the stimulation were collected. RESULTS: A total of 25 studies were included in the systematic review, comprising 135 patients. In the shorter term, most patients showed marked or satisfactory response to subthalamic DBS, although leucine rich repeat kinase 2 carriers of R114G mutations had higher rates of unsatisfactory outcome. Longer term follow-up data were scarce but suggested that motor benefit is sustained. Patients with the glucosidase beta acid (GBA) mutation showed higher rates of cognitive decline after surgery. Motor outcome was scarce for pallidal DBS. Few adverse events were reported. CONCLUSIONS: Subthalamic DBS results in positive outcomes in the short term in patients with Parkin, GBA, and leucine-rich repeat kinase 2 (non-R144G) mutations, although the small sample size limits the interpretation of our findings. Longer and larger cohorts of follow-up, with broader nonmotor symptom evaluations will be necessary to better customize DBS therapy in this population.
Entities:
Keywords:
Parkinson's disease; deep brain stimulation; genetics
Authors: E Sidransky; M A Nalls; J O Aasly; J Aharon-Peretz; G Annesi; E R Barbosa; A Bar-Shira; D Berg; J Bras; A Brice; C-M Chen; L N Clark; C Condroyer; E V De Marco; A Dürr; M J Eblan; S Fahn; M J Farrer; H-C Fung; Z Gan-Or; T Gasser; R Gershoni-Baruch; N Giladi; A Griffith; T Gurevich; C Januario; P Kropp; A E Lang; G-J Lee-Chen; S Lesage; K Marder; I F Mata; A Mirelman; J Mitsui; I Mizuta; G Nicoletti; C Oliveira; R Ottman; A Orr-Urtreger; L V Pereira; A Quattrone; E Rogaeva; A Rolfs; H Rosenbaum; R Rozenberg; A Samii; T Samaddar; C Schulte; M Sharma; A Singleton; M Spitz; E-K Tan; N Tayebi; T Toda; A R Troiano; S Tsuji; M Wittstock; T G Wolfsberg; Y-R Wu; C P Zabetian; Y Zhao; S G Ziegler Journal: N Engl J Med Date: 2009-10-22 Impact factor: 91.245
Authors: M L Welter; J L Houeto; S Tezenas du Montcel; V Mesnage; A M Bonnet; B Pillon; I Arnulf; B Pidoux; D Dormont; P Cornu; Y Agid Journal: Brain Date: 2002-03 Impact factor: 13.501
Authors: E Moro; J Volkmann; I R König; S Winkler; A Hiller; S Hassin-Baer; J Herzog; A Schnitzler; K Lohmann; M O Pinsker; J Voges; A Djarmatic; P Seibler; A M Lozano; E Rogaeva; A E Lang; G Deuschl; C Klein Journal: Neurology Date: 2008-04-01 Impact factor: 9.910
Authors: Paul Krack; Alina Batir; Nadège Van Blercom; Stephan Chabardes; Valérie Fraix; Claire Ardouin; Adnan Koudsie; Patricia Dowsey Limousin; Abdelhamid Benazzouz; Jean François LeBas; Alim-Louis Benabid; Pierre Pollak Journal: N Engl J Med Date: 2003-11-13 Impact factor: 91.245
Authors: Luigi M A Romito; Maria F Contarino; Daniele Ghezzi; Angelo Franzini; Barbara Garavaglia; Alberto Albanese Journal: J Neurol Date: 2005-02 Impact factor: 4.849
Authors: Gian Pal; Graziella Mangone; Emily J Hill; Bichun Ouyang; Yuanqing Liu; Vanessa Lythe; Debra Ehrlich; Rachel Saunders-Pullman; Vicki Shanker; Susan Bressman; Roy N Alcalay; Priscilla Garcia; Karen S Marder; Jan Aasly; M Maral Mouradian; Samantha Link; Marc Rosenbaum; Sharlet Anderson; Bryan Bernard; Robert Wilson; Glenn Stebbins; William C Nichols; Marie-Laure Welter; Sepehr Sani; Mitra Afshari; Leo Verhagen; Rob M A de Bie; Tom Foltynie; Deborah Hall; Jean-Christophe Corvol; Christopher G Goetz Journal: Ann Neurol Date: 2022-01-25 Impact factor: 11.274
Authors: Jolanta Dorszewska; Marta Kowalska; Michał Prendecki; Thomas Piekut; Joanna Kozłowska; Wojciech Kozubski Journal: Neural Regen Res Date: 2021-07 Impact factor: 5.135
Authors: Fabian J David; Miranda J Munoz; Jay L Shils; Michael W Pauciulo; Philip T Hale; William C Nichols; Mitra Afshari; Sepehr Sani; Leo Verhagen Metman; Daniel M Corcos; Gian D Pal Journal: Front Neurol Date: 2021-09-30 Impact factor: 4.003